Allogene Therapeutics (ALLO) Announces Pricing of $110 million Offering of Common Stock

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced the pricing of an underwritten offering of 37,931,035 shares of its common stock at a price of $2.90 per share. The gross proceeds from this offering are expected to be approximately $110 million, before deducting the underwriting discount and commissions and estimated offering expenses payable by Allogene.

The offering is anchored by mutual funds and large institutional investors and includes leading healthcare specialists as well as certain members of the Allogene Board of Directors and Executive Management Team. The offering is expected to close on or about May 16, 2024, subject to customary closing conditions.

Goldman Sachs & Co. LLC is acting as sole book-running manager for the offering.

You May Also Be Interested In

• Forbright completes $142.2 million IPO on Nasdaq
• MagnaChip (MX) files $50M mixed shelf
• Independence Realty Trust (IRT) files mixed shelf